Investing.com2d agoneutral
While biotech bets swing on trial data, this dividend payer gained 72% since 2024News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Business Wire3d agoneutral
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)GuruFocus.com8d agoneutral
Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Phase 3 ...MT Newswires10d agoneutral
Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC SaysGlobeNewswire10d agoneutral
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026Simply Wall St.46d agoneutral
How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease DataSimply Wall St.46d agoneutral
Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued?MarketBeat55d agoneutral
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond NeuroscienceSimply Wall St.66d agoneutral
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. PatientsSimply Wall St.67d agoneutral
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet DataInsider Monkey70d agoneutral
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks